Momelotinib Dihydrochloride
Sold as Ojjaara. Every branded application for this active ingredient.
- First approved: Sep 15, 2023
- Branded applications: 1
- New uses approved: 0
- Complete response letters: 0
Applications
NDAs and BLAs for this ingredient, oldest first; each opens its full history| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 15, 2023 | OjjaaraNDA 216873 · New molecular entity | Glaxosmithkline | 4 | Marketed |
GlaxosmithklineApplications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA